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Poster Session I S239received prior chemotherapy and 24% had received a prior stem cell
transplant. 48% of patients had not yet relapsed and 33% were cur-
rently symptomatic. Physicians were predominantly hematologists
(93%) who have been in practice on average for 12.2 years. 46% of
physicians reported being in a practice that includes stem cell trans-
plantation. For all participants, remission length was the major pos-
itive influence on choice (p\0.001), and toxicity of ALLO was the
major negative influence (p\0.001). Cost was a significant negative
influence on choice for physicians (p5 0.001), but not for patients.
By post-estimation analysis, patients were most likely to choose
AUTO (69%) and less likely to choose RIT (14%), CT (11%),
and ALLO (7%). The distribution for physicians was similar.
Conclusions: Patients with relapsed follicular lymphoma are able to
consider the advantages and disadvantages of various treatment op-
tions, and most are willing to trade off toxicity, hospitalization,
and cost associated with autologous transplantation in order to ben-
efit from increased remission length.218
CHRONIC GVHD AFTER ALLO-SCT WOULD BE NECESSARY FOR BETTER
OUTCOME OF ALLOGENIC STEMCELL TRANSPLANTATION (ALLO-SCT)
FOR CHEMOREFRACTORY NON-HODGKIN’S LYMPHOMAS -A SINGLE IN-
STITUTE RETROSPECTIVE STUDY
Nakano, N.1,2, Takatsuka, Y.1, Tokunaga, M.1, Takeuchi, S.1,
Kubota, A.1, Tokunaga, M.1, Utsunomiya, A.1 1 Imamura Bun-in Hospi-
tal, Kagoshima, Japan; 2Toranomon Hospital, Tokyo, Japan
Aims:The aims of this study are to identify the feasibility and clinical
characteristics of the patients undergone Allo-SCT for chemo-re-
fractory NHLs.
Design and methods: There were 55 NHL patients who had been
undergone allo-SCT in our institute from August 2001 to March
2009 consecutively. Thirty-seven patients out of 55 were adult T-
cell leukemia/lymphoma (ATLL) patients, and we analyzed about
rest of 18 patents. Study endpoints were 3 years overall survival
(OS), disease free survival (DFS) and these related factors.
Results: Median age was 37.5 yrs (19-63). Thirteen patients were
male and 5 female. Diagnosis included FL (n5 4), PTCL-u
(n5 3), MNKL (n5 3), BL (n5 2), DLBCL (n5 2), ALCL
(n5 1), T-LBL (n5 1), hepatosplenic lymphoma (n5 1), and MF
(n5 1). Median overall survival time and disease free survival time
after SCT were 215.5 days (6-2436) and 73 days (2-2436). Overall
survival rate after SCT was 38.9%. IPI was Low in 2 patients, 8 L-
I, 5 H-I, and 3 High. Low/L-I group showed significantly superior
OS, DFS compare to H-I/High group (54% vs 0%, 56.3% vs 0%).
HCT-CI scoring 0 in 12 patients, five 1, and only one patient scored
over 2. HCT-CI score significantly related to OS after SCT in our
cases. There were 13 sibling donors (included 5HLAhaplo-identical
donors) and 5 unrelated donors (URD) (included 2 cord blood do-
nors) in our cases. Ten patients received myeloablative conditioning
and 8 reduced intensity conditioning (RIC). Disease status at SCT
was CR in 5 patients, 7 PR, and 6 PD. Eleven patients died after
SCT (3 a-GVHD, 2 disease progression, 2 sepsis, 1 TMA, 1 pneu-
monia, 1 invasive aspergirosis, and 1 liver failure). Five patients
died within 100 days after SCT. Six patients have been alive over 3
years (3 yrs OS, DFS: 33.3%, 27.8%). Seven patients were compli-
cated grade 0-1 a-GVHD and 9 grade 2-4. Grade 0-1 group patients
showed significantly superior DFS compare to grade 2-4. Five pa-
tients complained limited c-GVHD and 3 extensive. The patients
group complained with c-GVHD showed better OS and DFS than
asymptomatic group (53.6% vs 12.0%, 58.3% vs 12.5%). Four pa-
tients suffered relapse or progressive disease after SCT. Two out
of these 4 patients showed GVL effect only with reducing immuno-
suppressive therapies.
Conclusion: Allo-SCT would be feasible therapy for chemorefrac-
tory NHLs. Chronic GVHD will be necessary and GVL effect
would be existed in our study.219
PRESENCE OF ABNORMAL PLASMA CELLS IN PERIPHERAL STEM CELL
HARVEST PRODUCTS PREDICT EARLY RELAPSE FOLLOWING AUTOLO-
GOUS STEM CELL TRANSPLANTATION IN PATIENTSWITHMULTIPLEMY-
ELOMA
Bakanay, S.M., Dalva, K., Koksoy, B.E., Civriz, S., Ayyildiz, E.,
Arat, M., Ozcan, M., Ilhan, O., Beksac, M. Ankara University, Ankara,
Turkey
Background: CD38 + 138+ stem cells more than 4.5 x10 5/kg has
been found to shorten overall survival (Kopp, 2009). The EBMT re-
port on the impact of plasma cell cytoreduction in apeheresis prod-
ucts has shown that despite major tumor cell elimination relapse
could not be eliminated(Bourhis, 2007). Flow cytometry has been
claimed to be of lesser specificity than PCR. The multiparametric
flow cytometry has the potential to quantify and distinct normal
plasma cells from abnormal plasma cells. The aim of this prospective
study was to analyze the amount of both normal and abnormal
plasma cells in peripheral stem cell products and correlate with clin-
ical outcome.
Patients: A total of 47 consecutive multiple myeloma patients who
were mobilized between March 2007 and July 2009 were included
in the study. Patients were male/female: 26/21; ISS: I/II/III: 17/
18/11; age: 54 (35 -65). Treatment preceding transplant consisted
of novel agent including protocols (n: 13) or excluding protocols(n:
34). Plasma cell quantification was done using a panel of monoclonal
antibodies by using multiparameter flowcytometry. If any aberrant
expression (such as CD20(loss) CD27(loss) CD28 (gain),
CD33(loss), CD34 (gain), CD81(loss), CD117(gain)) were detected
at diagnosis, the corresponding antibody was also added to the panel.
Results: Abnormal plasma cells were detected in 9 apheresis prod-
ucts from 8 patients. The median plasma cell count (normal plus ab-
normal) was 6.53 (0,19-542) x 105/kg. In the abnormal plasma cell
positive group the median total and abnormal plasma cell counts
were 2.73 (0.19-542) x105/kg and 1.4 (0.07-542) x105/kg, respec-
tively. Twenty five patients had $4.5 x105/kg (high) plasma cells
while 17 patients has\4.5 x105/kg (low) plasma cells.Similar rate
of response (.5 PR) was obtained in 5/7 patients with plasma cell
contamination following transplantation. Amongst 18 patients evalu-
able during post transplant 1 year follow up, 10 of the 12(83%) pa-
tients who had high plasma cell count and 3 of 6 (50%) patients
who had low plasma cell count in their products, either progressed
or relapsed.
Conclusion: High dose therapy with stem cell support may induce
high hematological responses confirmed by reduction inmonoclonal
protein production. Patients who have lower amount of plasma cell
contaminating the apheresis products seem to perform better out-
come during the first year follow up after transplantation.
Table 1.
PostResponse
Pre
Mobilisation
Pre
Transplant
Transplant
month2Relapse
\1 yearAbnormal plasma cell
positive6/7 4/7 5/7 4/7Abnormal plasma cell
negative31/34 27/34 27/32 4/13Total 37/41 31/41 7/39 8/20220
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA: WHAT PREDICTS THE OUT-
COME?
Kumar, L., Ganess, P., Gogia, A., Ghosh, I., Hariprasad, R. All India In-
stitute of Medical Sciences, New Delhi, Delhi, India; All India Institute of
Medical Sciences, New Delhi, Delhi, India; All India Institute of Medical
Sciences, New Delhi, Delhi, India; All India Institute of Medical Sciences,
New Delhi, Delhi, India; All India Institute of Medical Sciences, New
Delhi, Delhi, India
We analyzed results of 118 patients (84 males and 34 females) of
multiple myeloma who underwent autologous stem cell
S240 Poster Session Itransplantation (ASCT) at our institute till december, 2007. Pa-
tients’ median age was 52 years (range, 26 to 68 years). High
dose melphalan (200 mg/m2) was used for conditioning. 86
(72.8%) patients had evidence of chemo-sensitive disease prior
to transplant. Response was defined as per EBMT criteria. Fol-
lowing ASCT 80.5% of patients responded; complete (CR) –
46(39%), very good partial response-31(26.3%), and partial re-
sponse-18(15.3%). CR rate was higher for patients with chemo-
sensitive disease; 44 of 86 patients (51.0%) achieved CR com-
pared to 2 of 32 patients (6.2%) with chemo-resistant disease,
p\.001. Response rate to transplant was higher for patients
with serum albumin. 3.3 mg% (p5 0.03), ISS stage- I-II at di-
agnosis (p5 0.001) and Durie-Salmon stage IIIA, p5 0.001. At
a median follow up of 83 months (range, 22 to 155 months),
the median overall (OS) and event-free survival (EFS) is 72
and 29 months, respectively. Estimated OS and EFS at 60
months is 54.2% 6 0.05% (SE) and 32% 6 0.05(SE), respec-
tively. Patients who achieved CR (median not reached yet,
mean 171.91 months +/- 16.2 (SE)) and very good PR (median
84 months) following transplant had a significantly better survival
compared to those with PR (median 38 months,p5 0.0001). Pre-
transplant chemo-sensitive disease (OS: p5 0.006, EFS:
p5 0.007), ISS stage I-II (EFS: p5 0.008) and response to trans-
plant (OS and EFS: p5 0.0001) were important predictors of
survival on multivariate analysis. Six patients (Four disease-free)
were alive at .120 months follow up; all six had pre-transplant
chemo-sensitive disease and had achieved CR after transplant.
Conclusion: Patients with pre-transplant chemo-sensitive disease
and those who achieve complete response following transplant ben-
efit maximum.221
HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPIETIC PROGENITOR
CELL TRANSPLANTATION FOR RECURRENT OR REFRACTORY HODG-
KIN’S LYMPHOMA: ANALYSIS OF KING HUSSEIN CANCER CENTER
(KHCC) RESULTS AND PROGNOSTIC VARIABLES
Abdel-Rahman, F.A., El Taani, H.A., Badheeb, A., AlJmili, M., El-
Khatib, H.M., Ahmed, A., Alzabin, A., Rihani, R., Hussein, N.,
Sarhan, M. King Hussein Cancer Center, Amman, Jordan
Purpose: to evaluate the outcome of patients with Hodgkin’s lym-
phoma who underwent autologus hematopoietic stem cell transplan-
tation at the young KHCC bone marrow transplant (BMT)
program.
Patients and Methods: Over the past 6 years, 63 patients with re-
lapsed or refractory Hodgkin’s lymphoma underwent high dose che-
motherapy followed by autologus stem cell transplant. Among the
group there were 54 adults, and 9 children. The median age was
27 years, and 61% of the patients were males.
There were 16 (25.4%) patients in complete remission (CR), 45
(71.4%) with chemotherapy responsive disease and 2 patients (3%)
with stable disease. Prior to conditioning regimen, 35 patients
(56%) received two chemotherapy lines only, and 28 patients
(44%) received more than two lines.
All patients except three received BEAM as pre transplant condi-
tioning.
Results: the main end points of the study are the rate of complete
remission at day 100, overall survival(OS), relapse-free survival
(RFS), correlation of the following variables withOS and RFS: a-dis-
ease status at the time of transplant, b-number of chemotherapy lines
prior to conditioning c-age group.
The median follow up time was 16.0 months (range, 1.25-
44.4months).
The day 100 non-relapse mortality was 4.8%.
The CR at day 100 was 57% (25% before transplant).The median
overall survival for the whole group were 40.6 months, the median
RFS was not reached but currently 63% are still relapse-free.
When we looked at the three variables in correlation with OS,
and RFS in aunivarient analysis, the only statistically significant
correlation was between the number of chemotherapy lines prior
to conditioning and OS, with p value 0.049 in favor of patients
received two lines only. In all other correlations the p value
was not significant.Conclusion: Despite its young age, our program is able to perform
autologous stemcell transplantation forHodgkinDisease at a reason-
ably acceptable mortality and with an outcome comparable to pub-
lished data.
In our study only the number of chemotherapy lines received be-
fore conditioning had statistically significant correlation with OS.
The disease status at the time of transplant did not have statisti-
cally significant correlation with survival, this is contradicting
some of the published literature, however; this could be mainly
due to the small number of patients, 16 (25%): CR and 45
(71.4%): responsive disease. A complete analysis of data will be pre-
sented at the meeting.PEDIATRIC DISORDERS
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STEM CELL TRANSPLANTATION FOR NIJMEGEN BREAKAGE SYNDROME
Albert, M.H.1, Gennery, A.R.2, Greil, J.3, Cale, C.M.4, Kalwak, K.5,
Kondratenko, I.6, Mlynarski, W.7, Stachel, D.K.8, Notheis, G.1,
Fu¨hrer, M.1, Schmid, I.1, Belohradsky, B.H.1 1Dr. von Haunersches
Kinderspital, Munich, Germany; 2Newcastle General Hospital, Newcastle,
United Kingdom; 3University Hospital, Heidelberg, Germany; 4Great
Ormond Street Hospital, London, United Kingdom; 5Pediatric Hematolo-
gy/Oncology/BMT,Wroclaw, Poland; 6Russian Children’s Clinical Hospi-
tal, Moscow, Russian Federation; 7Medical University of Lodz, Lodz,
Poland; 8Kinderklinik der Universita¨t, Erlangen, Germany
Nijmegen breakage syndrome (NBS) is a rare autosomal recessive
disorder characterized by immunodeficiency, characteristic facial ap-
pearance, chromosomal instability, X-ray hypersensitivity, and pre-
disposition to malignancy. About 40% of patients develop
malignancy mostly of lymphoid origin before age 21. Traditionally
NBS patients have not undergone stem cell transplantation (SCT)
owing to concerns about chromosomal instability and increased tox-
icity. But in the case of resistant or relapsingmalignancy SCTmay be
the only therapeutic option. We therefore analyzed the transplant
experience in NBS patients in Europe.
A total of six genetically confirmed NBS patients were included.
Median age at diagnosis was 7.6 years (range 1-18) and 14.5 years
(range 2.3-20.3) at transplant. The reason to attempt SCTwas resis-
tant or secondary malignancy in four cases. The other two were
transplanted because of severe immunodeficiency or suspected Fan-
coni anemia with immunodeficiency. All had a quantitative and func-
tional T-cell defect and 4/6 had deficient humoral immunity before
transplant. Five patients received reduced intensity regimens with in
vivo T-cell depleting agents. The donors were MSD in 3 patients,
one haploidentical parent and two MUD.
At a median follow up of 3.0 years (range 2.4-9.1) five of six pa-
tients are alive and well. Three patients had no relevant transplant re-
lated complications. One patient died on day +5 from sepsis. He had
received a BMT from a matched sibling after a myeloablative, busul-
fan containing conditioning regimen. Acute GVHD grade I-II oc-
curred in 3/5 patients, mild chronic GVHD in one. Four patients
have complete donor chimerism, one has mixed chimerism, but all
five exhibit restored T-cell immunity.
Although very limited, the experience in these six patients clearly
suggests that SCT in NBS is feasible, can correct the immunodefi-
ciency and effectively treat malignancy. Acute toxicity seems to be
reasonable with reduced intensity conditioning regimens.However,
valid concerns remain about increasing the risk for subsequent ma-
lignancy through cytotoxic agents in these patients.223
POSTGRAFTING IMMUNE SUPPRESSION COMBINEDWITH NONMYELOA-
BLATIVE CONDITIONING FOR TRANSPLANTATION OF HLA-MATCHED
RELATED OR UNRELATED HEMATOPOETIC CELL GRAFTS: PRELIMINARY
RESULTS OF A PHASE II STUDY FOR TREATMENT OF PRIMARY IMMUNO-
DEFICIENCY DISORDERS
Burroughs, L.1,2, Storb, R.1,2, Leisenring, W.1, Torgerson, T.2,
Nemecek, E.3, Frangoul, H.4, Walters, M.5, Scharenberg, A.2,
Rawlings, D.2, Skoda-Smith, S.2, Ochs, H.2,Woolfrey, A.1,2 1FredHutch-
inson Cancer Research Center, Seattle, WA; 2University of Washington
School of Medicine; 3Oregon Health & Sciences University; 4Vanderbilt
University; 5Children’s Hospital, Oakland, CA
